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Growth hormone (GH) has been shown to act directly on multiple tissues
throughout the body. Historically, it was believed that GH acted directly in
the liver and only indirectly in other tissues via insulin-like growth hormone
1 (IGF-1). Despite extensive work to describe GH action in individual tis-
sues, a comparative analysis of acute GH signaling in key metabolic tissues
has not been performed. Herein, we address this knowledge gap. Acute tis-
sue response to human recombinant GH was assessed in mice by measuring
signaling via phospho-STAT5 immunoblotting. STAT5 activation is an
easily and reliably detected early marker of GH receptor engagement. We
found differential tissue sensitivities; liver and kidney were equally GH-sen-
sitive and more sensitive than white adipose tissue, heart, and muscle (gas-
trocnemius). Gastrocnemius had the greatest maximal response compared
to heart, liver, white adipose tissue, and whole kidney. Differences in maxi-
mum responsiveness were positively correlated with tissue STAT5 abun-
dance, while differences in sensitivity were not explained by differences in
GH receptor levels. Thus, GH sensitivity and responsiveness of distinct
metabolic tissues differ and may impact physiology and disease.
Growth hormone (GH), produced in the anterior pitu-
itary, plays a major role in both longitudinal growth
and metabolism [1,2]. Dysregulation in GH signaling,
either increased in acromegaly and gigantism [3] or
decreased in short stature or dwarfism, has profound
consequences on growth and development [4,5]. GH
also impacts life span; GH excess is associated with
increased morbidity and premature mortality [6], while
GH deficiency promotes longevity [7]. GH binds cell
surface receptors (GH receptor; GHR) on target cells,
resulting in GHR-associated Janus kinase 2 (JAK2)
autophosphorylation and subsequent phosphorylation
of GHR intracellular domain tyrosine residues [8–13].
Signal transducer and activator of transcription 5
(STAT5) docks at the phosphorylated GHR and is
phosphorylated by JAK2. pSTAT5 dimers translocate
to the nucleus to influence transcription of genes
including insulin-like growth factor (IGF)-1 [14–16];
GH’s metabolic and somatogenic effects are related to
its influence on target cell gene expression.
Assessing acute GH effects in different key meta-
bolic tissues may have once been considered an irrele-
vant question. Classically, GH was thought to
exclusively target the liver, which would then produce
IGF-1 (aka somatomedin C) [17]. IGF-1 would subse-
quently act in an endocrine manner, modulating
growth/metabolism in extrahepatic tissues. This is the
somatomedin hypothesis of GH action [18]. Later,
D’Ercole et al. [19] showed that IGF-1 is also pro-
duced locally by extrahepatic tissues in response to
Abbreviations
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GH and that the level of IGF-1 produced after GH
administration differs between tissues. Further, Skot-
tner et al. [20] demonstrated that administration of
IGF-1 did not affect longitudinal growth in hypophy-
sectomized rats, except at very high concentrations,
whereas GH administration induced significant
growth. These pioneering studies suggested that IGF-1
might be produced and act locally within target tis-
sues, in contrast to the somatomedin hypothesis. Con-
sistent with these observations, liver-specific IGF-1
knockout mice grow and develop normally, despite
diminished circulating IGF-1 [21–23]. As such, a
revised hypothesis suggests that circulating (hepatic-
derived) IGF-1 is responsible for negatively regulating
GH secretion, whereas local (extrahepatic) IGF-1 plays
a primary role in longitudinal growth [24].
Despite interest in extrahepatic actions of GH and
IGF-1, little information is available that compares
GH signaling among organs in intact animals. Because
of the distinct roles of GH signaling in the liver com-
pared to other metabolic tissues, we hypothesized that
GH sensitivity and responsiveness would differ in hep-
atic versus extrahepatic tissues. Herein, we compare
acute in vivo sensitivity and MAX responsiveness to
exogenously administered GH in mice among liver,
heart, kidney, skeletal muscle (gastrocnemius; gastroc),
and epididymal white adipose tissue (eWAT). Our
results indicate substantial differences between tissues
that may be important for understanding tissue-specific
metabolic and growth-promoting effects of GH.
Materials and methods
Unless otherwise stated, reagents were obtained from
Sigma (St. Louis, MO).
Animals
All animal husbandry and experimental protocols were car-
ried out according to the Guide for the Care and Use of
Laboratory Animals [1996 (7th ed.), Washington, DC:
National Research Council, National Academies Press] and
in compliance with the local IACUC standards. At
15 weeks of age ( 3 days), male C57B6J mice (Jackson
Laboratories; Cat. # 000664) were individually housed in
standard conditions under a 12-h : 12-h light:dark cycle
and had ad libitum access to standard rodent chow and
water. After acclimatization to single housing, mice were
placed in wire-bottom cages without food at the beginning
of the light cycle. Growth hormone challenge was per-
formed in 6-h fasted mice in a manner that is essentially
identical to that described previously [25]. Briefly, either
saline (control) or human recombinant GH (2, 4, 8, 12.5,
20, 50, 80, 120, 200 ng/gbw; gift from Eli Lilly Co, Indi-
anapolis, IN) was injected (i.v.) in anesthetized mice; 5 min
thereafter, heart, liver, kidney, eWAT, and gastroc were
rapidly excised in that order and flash-frozen in liquid
nitrogen prior to biochemical analysis. Total time of tissue
extraction for each animal was 3–4 min. The duration of
GH exposure was selected so as to capture only acute (and
not secondary) effects of GH stimulation and thus most
cleanly address the question of GH sensitivity.
Liver samples for PRLR mRNA positive control were
harvested from female C56Bl6/J mice that were ad libitum
fed and age-matched, age 2–3 months. Pregnant samples
were harvested at gestational day 16.5.
This study protocol was approved by the University of
Alabama at Birmingham Institutional Animal Care and
Use Committee.
Immunoblotting
Protein lysates were prepared from tissues crushed to pow-
der under liquid nitrogen (~ 20 mg) using 300 lL of tissue
lysis buffer (50 mM Tris 7.3, 150 mM NaCl, 1 mM EDTA
pH 8.1, 1.5 mM MgCl2, 10% glycerol, 1% Triton X-100,
10 mM Na4P2O7, 100 mM NaF, 1 mM Na3VO4, 1 mM
phenylmethanesulfonyl fluoride, 5 lgmL1 aprotinin, and
5 lgmL1 leupeptin). Lysates were resolved under reducing
conditions by SDS/PAGE and transferred to nitrocellulose
membranes (Amersham Biosciences), followed by blocking
with 2% BSA. Membranes were immunoblotted (Table 1)
with anti-phospho-STAT5 antibody (Y694; Cell Signaling;
9351L) (1 : 1000), which reacts with both phosphorylated
Y694 in STAT5A and Y699 in STAT5B; anti-STAT5
antibody (Santa Cruz Biotechnology; sc-835) (1 : 1000);
anti-GHR (polyclonal anti-GHRcytAL-47; against the intra-
cellular domain of GHR) [26] (1 : 1000); anti-PRLR (anti-
PRLRcytAL-84; against the human PRLR ICD) [27]
(1 : 1000); anti-PRL-R (H-300) (Santa Cruz Biotechnology;
sc-20992); and anti-JAK2 (anti-JAK2AL-33) [28] (1 : 1000).
Densitometry was performed using UVP Software 8.0.
Curve fitting and statistical analysis
Dose–response curve data were fit to the sigmoidal dose–
response curve (with variable slope): [Y = BOTTOM +
(TOP-BOTTOM)/(1 + 10^((LogEC50-X)*HillSlope))]; Y =
response; X = log[dose]; HillSlope = slope of linear section
of the dose–response curve; TOP = point in the dose–
response curve at which an increase in ‘X’ yields little to no
increase in ‘Y’; and EC50 = the effective concentration (or
dose) at which 50% of the MAX response is achieved [29].
This analysis was performed using GraphPad Prism version
4.00 for Windows (GraphPad Software, San Diego, Califor-
nia, USA, www.graphpad.com). Sensitivity was defined by
the value EC50. Responsiveness was defined by the TOP
value, herein referred to as the MAX response. During the
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constrained fit, the TOP and BOTTOM parameters were
fixed at 100 and 0, respectively. Tissue-specific differences in
protein abundances were assessed via one-way ANOVA
using SPSS followed by post hoc analysis via Tukey’s test.
Regression analysis to assess the correlation between STAT5
abundance and MAX response was performed using Excel.
Gene analysis
mRNA was isolated from mouse tissues using either a
QIAGEN RNeasy Mini Kit (Cat. No. 74104) or TRIzol
RNA isolation reagent according to the manufacturer’s rec-
ommended protocol for RNA isolation. Reverse transcrip-
tion was performed using the High-Capacity cDNA RT
Kit (Cat. No. 4368814) from Thermo Fisher. qPCR mea-
surements were carried out using the mPRLR TaqMan
Gene Exp. Assay (Assay ID Mm04336676_m1, Cat. No.
4351372) from Thermo Fisher.
Data display
Due to differences in normalizing proteins across tissues,
densitometry data are normalized to total protein loaded on
the gel except in Fig. 2 where pSTAT5 is normalized to
STAT5 as a loading control; tissue differences in STAT5
abundance do not influence sensitivity. To reduce positional
bias during the immunoblot transfer procedure, samples were
loaded on gels in randomized order; where possible, n = 1 for
each GH dose was included on each gel. Densitometry was
performed on nonmanipulated blots. For clarity, representa-
tive blots presented were constructed as follows: A single gel
was chosen for each tissue, after which lanes were rearranged
such that GH doses were displayed in ascending order.
Results
Murine peripheral tissues display differential
sensitivity and MAX response to GH
Although they varied greatly in responsiveness, with
kidney being the least maximally responsive, all tissues
examined displayed dose-dependent GH effects on
STAT5 phosphorylation (Figs 1A and 2). Calculation
of EC50 values (see the Methods section for details)
revealed tissue-specific differences in GH sensitivity
(Fig. 1B, Table 2). EC50 values for liver and kidney did
Table 1. Antibody table.
Antigen sequence (if known) Name of antibody
Manufacturer, catalog #,







Y694, mouse, rat, bovine, human Anti-pSTAT5 Cell Signaling, 9351L Rabbit; polyclonal 1 : 1000 AB_331594
Stat5 (C-17) human, mouse, rat STAT5 (C-17) Santa Cruz, Cat. # sc-836 Rabbit; polyclonal 1 : 1000 AB_632446
Residues 271-620 Anti-GHRcytAL-47 Stuart J. Frank Rabbit; polyclonal 1 : 1000 AB_2713931
PRLR intracellular domain Anti-PRLRcytAL-48 Stuart J. Frank Rabbit; polyclonal 1 : 1000 AB_2665406
Residues 323-622 PRL-R (H-300) Santa Cruz, Cat. # sc-20992 Rabbit; polyclonal 1 : 1000 AB_2237692
Residues 746-1129 Anti-JAK2AL-33 Stuart J. Frank Rabbit; polyclonal 1 : 1000 AB_2665398
Fig. 1. Tissue GH sensitivity and responsiveness (free fit). (A) Representative blots for dose-dependent GH-induced STAT5 phosphorylation
in liver, kidney, eWAT, heart, and gastrocnemius muscle. The exposure of the blots was adjusted to be able to visualize dose dependencies
of the different tissues, and as such, the intensities of bands may not be compared between tissues. (B) Dose–response data from liver,
kidney, eWAT, heart, and gastrocnemius fit to the Hill equation without fit constraints (mean  SEM; n = 3–10).
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not differ significantly, although both were substantially
lower (i.e., greater sensitivity) than eWAT, heart, and gas-
trocnemius. Differences were likewise observed in tissue
responsiveness (Fig. 1B, Table 2). Gastrocnemius had
the greatest (extrapolated) MAX GH response, followed
by heart, liver, eWAT, and kidney (Fig. 1B, Table 2).
There was large variability (i.e., confidence intervals) in
the EC50 and MAX values for gastrocnemius, heart, and
eWAT because the predicted MAX value was not defined
by experimental data points (as predicted GH doses
required for MAX response were too high). Therefore, as
a secondary analysis we normalized the data for each
curve such that the highest experimental data point was
100 while the lowest was 0, and fit the data to the sig-
moidal dose–response curve using the constraints
TOP = 100 and BOTTOM = 0 (Fig. 2). This analysis
yielded similar EC50 calculations for liver and kidney, as
well as similar R2 values for all curve fits. Furthermore, it
confirmed, statistically, that liver and kidney have the
same EC50 and that they are significantly more sensitive
than eWAT, heart, and gastrocnemius (Fig. 2, Table 2).
Differential abundance of GH signaling proteins
among tissues
The factors that influence tissue sensitivity to a hormone
often reside at the level of the receptor. Accordingly, we
assessed GHR abundance by immunoblotting with an
antibody against the GHR intracellular domain, which
revealed highest abundance in eWAT (2.05 A.U.), fol-
lowed by liver (1.00 A.U.), heart (0.61 A.U.), kidney
(0.29 A.U.), and gastrocnemius (0.28 A.U.) (Fig. 3A,E).
This study utilized human GH, which can also induce
STAT5 phosphorylation via the prolactin receptor
(PRLR) [30–32]. We compared PRLR-expressing
MIN6 cells to the relevant mouse tissues by
immunoblotting with two distinct anti-PRLR sera (anti-
PRLRcytAL-84 and anti-PRL-R (H-300); Fig. 4A,B,
respectively). No bands in common were detected by
these sera in the mouse tissues, but a common PRLR
band was detected by both in the MIN6 positive con-
trol. Analysis of prlr mRNA levels validated the conclu-
sion that little or no expression was detected in the
mouse tissues tested (Fig. 5). Thus, analyses of GHR
and PRLR abundance did not readily explain observed
tissue-specific differences in GH sensitivity (although
relatively high GHR expression in the liver may con-
tribute to elevated GH sensitivity in this tissue).
In contrast to hormone sensitivity, the responsive-
ness of a tissue to a hormone is influenced by factors
downstream of the receptor, including abundance of
downstream signaling molecules. To this end, we
assessed JAK2 and STAT5 abundance by immunoblot-
ting. Relatively modest differences were observed in
JAK2 abundance, with lowest levels in gastrocnemius
and highest levels in kidney (Fig. 3B,F). STAT5 abun-
dance did not differ between liver, gastrocnemius, and
heart, but was significantly lower in eWAT and kidney
(Fig. 3C,G). Regression analysis revealed a correlation
(correlation coefficient: + 0.8296) between the STAT5
abundance in a tissue and its MAX response
(P = 0.082) (Fig. 3D).
Fig. 2. Tissue GH sensitivity (constrained fit). Dose–response data
normalized such that the highest value within each tissue is 100
and lowest is 0, and fit to the Hill equation with the constraints:
TOP = 100 and BOTTOM = 0.
Table 2. Curve fit parameters: from fitting dose–response data from Fig. 1B to the Hill equation without constraints (free fit), and from
Fig. 2 using fit constraints (constrained fit).
Liver Kidney eWAT Heart Gastroc
Free fit
EC50 (ng/gbw) 10 14 1248 4901 1642
MAX response (A.U.) 104.3 1.8 53.6 296.1 615.2
R2 0.8622 0.65 0.6343 0.6928 0.7379
Constrained fit
EC50 (ng/gbw) 11 14 46 63 82
EC50 (ng/gbw) 95% CI 7.7–16.9 9.2–20.9 30.9–67.1 47.0–83.9 65.0–103.5
R2 0.7344 0.6744 0.6288 0.722 0.7241
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Discussion
The purpose of the current study was to define
tissue-specific differences in GH sensitivity and MAX
responsiveness to GH. Here, we report that the order of
GH sensitivity was liver = kidney > eWAT = heart = gas-
trocnemius, while the order of GH MAX responsiveness
was gastrocnemius > heart > liver > eWAT > kidney
and roughly correlated with STAT5 protein abundance.
Such observations lead to questions with regard to physi-
ologic significance. While the MAX response predicted
from the free curve fitting in gastrocnemius and heart
was much greater than in the other tissues, the levels of








Fig. 3. GH signaling components.
Densitometry analysis and representative
blots of tissue-specific comparison of
protein abundance for (A,E) GHR, (B,F)
JAK2, and (C,G) STAT5 (relative to liver)
(mean  SEM; n = 5). Significance: All
symbols represent P < 0.05 compared to:
*, liver; #, gastrocnemius; §, heart; Φ,
eWAT; and Ψ, kidney. (D) Linear
regression analysis displaying the
correlation between tissue-specific MAX
response and STAT5 (mean; n = 5)




Fig. 4. PRLR immunoblot of tissue lysates
from various mouse tissues and in MIN6
mouse insulinoma cells (positive control).
The black arrows denote the PRLR in the
IP control. () denotes that no
immunoprecipitation was performed. NI
denotes nonimmune serum.
Immunoprecipitation was performed with
anti-PRLRcytAL-84, and resolved eluates
were immunoblotted sequentially with
(A) anti-PRLRcytAL-84 and (B) anti-PRL-R
(H-300).
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beyond physiologic levels. However, despite the error
in these predicted values being large, the fact that there
was a near-significant correlation between STAT5 and
MAX response supports the idea that these values are
good estimates. The liver and kidney exhibit the high-
est level of GH sensitivity (relative to other tissues
investigated), and the other three tissues were indistin-
guishable statistically. That this general relationship
holds true regardless of whether constraints were used
supports the idea that the liver and kidney respond to
GH at much lower concentrations than eWAT, heart,
and gastrocnemius.
Growth hormone plays a number of important roles
in the liver, including generation of circulating IGF-1
(which acts in a negative feedback manner on GH
secretion) and hepatic metabolism. In the latter case,
GH effects generally oppose those of insulin; specifi-
cally, these effects suppress glycolysis in favor of fatty
acid oxidation and promote glycogenolysis and in pro-
longed fasting conditions promote gluconeogenesis
[1,33–36]. Thus, increased GH secretion during sleep
likely plays an important role in maintenance of blood
glucose levels via multiple mechanisms. Interestingly,
the kidney is also a gluconeogenic tissue, contributing
up to 50% of endogenous glucose production in the
starved state [37]. GH signaling in the kidney is also
important for normal sodium and water retention; GH
deficiency leads to renal insufficiency, while excess leads
to hypertension, renal hypertrophy, and failure [37].
Thus, our observation that the kidney is relatively GH-
sensitive (similar to the liver) is consistent with essential
GH actions in this tissue. GH signaling is also impor-
tant in eWAT, as this endocrine factor shifts metabo-
lism from glucose utilization toward lipolysis and fatty
acid oxidation, thereby minimizing reliance on muscle
protein catabolism during periods of fasting (such as
the sleep period) [1,38–40]. In contrast, GH signaling in
the adult heart must be closely regulated, thus prevent-
ing excessive growth (e.g., in acromegaly) and subse-
quent contractile dysfunction [41]. Similar to the heart,
GH signaling in skeletal muscle mainly influences
muscle size, but not contractile force [38,40,42]. Our
observation that skeletal muscle has decreased respon-
siveness to circulating GH may be explained by the
existence of mechano growth factor (MGF), an alterna-
tive splice variant of the igf-1 gene. MGF expression is
increased in response to muscle stretch and exercise
[43]. Even hypophysectomized mice retain the ability to
upregulate MGF in response to exercise [43,44]. The
low GH sensitivity of gastrocnemius muscle may sug-
gest that skeletal muscle growth in an adult mouse, in
response to exercise, for example, may be through
GH-independent mechanisms.
Subsequent interrogation of known GH signaling
components provided potential mechanistic insights
with regard to tissue-specific differences in GH respon-
siveness/sensitivity. For example, STAT5 levels were
correlated with MAX response in a given tissue. Addi-
tionally, GHR levels were relatively high in liver, consis-
tent with high GH sensitivity. Our findings are
consistent with those of Walker et al. [45], who reported
that GHR mRNA in the rat kidney was roughly 33%
that of liver. Additional studies are required to elucidate
fully the mechanisms mediating tissue-specific differ-
ences in GH sensitivity/responsiveness.
The current study focused on a particular acute sig-
naling response of various tissues to exogenously
administered GH (namely STAT5 phosphorylation).
This approach has benefits and drawbacks. Although
we did not assess the long-term response to endoge-
nous GH pulses, this approach allowed us to directly
compare acute responses to GH in multiple tissues
simultaneously. As STAT5 is a critical mediator of
acute GH action, we were able to observe direct GH
effects, rather than compensatory effects over longer
periods. Nonetheless, we acknowledge that our studies
do not discriminate between the STAT5A and
STAT5B isoforms of STAT5. As different tissues may
express varying ratios of these isoforms, our conclu-
sions concerning maximum responsiveness based on
STAT5 abundance should be interpreted with caution.
As noted above, GH stimulates glycogenolysis in
liver and kidney during fasting [35,36]. The mice in
this study were fasted for 6 h prior to GH treatment.
Therefore, it is possible that we would have observed a
different relationship among tissues of GH sensitivity
in mice if food had not been withdrawn in the 6 h
Fig. 5. Comparison of PRLR mRNA expression between the male
mouse tissues and with livers from pregnant and nonpregnant
female mice. M, male; NPF, nonpregnant virgin female; PF,
pregnant female. Data represented as mean  SEM; n = 3-5 for
each condition.
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leading up to GH treatment. However, the period of
fasting corresponded to the first 6 h of the rest phase,
during which food consumption is generally reduced
(relative fasting), compared to the active period [46].
Thus, the relative physiologic effects of the strict fast
are likely limited. We are mindful, however, that GH
sensitivity and MAX response were only assessed at
one time of day in our study. Because the circadian
clock may control both secretion and sensitivity to
hormones [47], it is possible that relative tissue sensi-
tivity to GH may vary depending on the time of day.
In summary, the current study reveals a correlation
between STAT5 abundance and the MAX GH
response in these tissues, while GH sensitivity is not
correlated with GHR. Thus, an important determinant
of MAX GH response appears to be STAT5 abun-
dance, while the determinants of in vivo GH sensitivity
are more complex. We speculate that in pathological
states, GH action may be influenced by alterations in
GH sensitivity and/or responsiveness, not solely by
changes in circulating GH levels. Our data from wild-
type mice will serve as a template for analyzing such
changes in disease states.
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